Salt Composition in both
Medroxyprogesterone acetate 150mg
Salt Composition
(same for both)
You Searched
Strip of 10 tablets
We only sell the best substitute from top brands
Our Recommendation
Gestoserv M 150mg Tablet 10s
2,334+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Requesting the Medicine (a require for doctor consultation)1 review (2 reviews) Totalof 6 orders
Report suspected compromise or errors when accessing this website.
Report any issues that appear on this platformReport any side effects that appeared on this platformReferencesTREATLEfor
NOVEL
PITTSBURGH, Oct 12, 2009/PRNewswire/ -- Abreva Pharmaceuticals (NYSE: ABR) today announced financial results for the fourth quarter of 2009.
"The year-over-year high of $16.6 billion resulted in $4.3 billion in net income and $1.9 billion in net income impairment due to the loss of exclusivity on a generic version of Provera®," said John T. Crampton, President and Chief Executive Officer of Abreva Pharmaceuticals. "Our results reflect continued strong momentum and demonstrated strong growth and we continue to build on our success and continue to deliver."
Abreva will continue to be the subject of significant growth from our fourth quarter of 2008 through 2011, as we continue to increase our product portfolio through our first-ever quarter of full-year 2008 financial guidance. Abreva expects the full-year 2008 results to be in line with our 2011 results, which are expected to be in line with our full-year 2008 results.
For the quarter, Abreva reported a net income of $4.3 billion, which included $1.9 billion in net income impairment due to the loss of exclusivity on a generic version of Provera®. The impact of the loss of exclusivity, including the impact of the impact of the impact of the year-over-year high of $16.6 billion on net income, was primarily due to the impact of the loss of exclusivity on a generic version of Provera®. We believe that Abreva's performance in the fourth quarter of 2008 will continue to be well-suited to the full-year 2008 results. As such, our results will continue to be well-suited to the full-year 2008 results.
In the fourth quarter of 2008, Abreva reported revenue of $4.3 billion, which included $1.9 billion in net income impairment due to the loss of exclusivity on a generic version of Provera®.
For the quarter, Abreva reported revenue of $4.3 billion, which included $1.9 billion in net income impairment due to the loss of exclusivity on a generic version of Provera®.
In the fourth quarter of 2008, Abreva reported revenue of $4.
Depo-Provera Injection is used as a contraceptive to prevent pregnancy. Administered every three months, it contains medroxyprogesterone acetate, a progestin hormone that prevents ovulation, thickens cervical mucus, and thins the uterine lining, reducing the likelihood of fertilization and implantation. This method of birth control is suitable for women seeking long-term contraception without daily pills. Besides pregnancy prevention, it may be prescribed to manage menstrual disorders and reduce endometriosis-related pain. Regular medical monitoring is recommended to manage potential side effects and ensure ongoing suitability.
Depo-Provera Injection by Pfizer is a leading contraceptive solution offering significant convenience and effectiveness. Here is a detailed description of the benefits of using Depo-Provera Injection:
Disclaimer:The information and content posted on this website is intended for informational purposes only and is not intended to be used as a replacement for medical advice. Always seek medical advice from a medical professional for diagnosis or treatment, as they may properly assess your specific health condition and provide correct treatment and answer any questions you may have regarding medical information or medical symptoms.
Fertile2 mL for injection, 150 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.6 mL vial, 10.The United States Food and Drug Administration (FDA) has approved the Depo Provera shot, the first contraceptive to undergo clinical trials in women with the disorder.
The Depo Provera shot was developed to reduce the risk of birth defects in a fetus with the disorder because it’s a “safest birth control method” (SBCC) for women at risk. The birth control pill, Depo-Provera, was approved in October 2014.
The Depo Provera shot is an injectable contraceptive that has been in use since at least 17 years, and was approved in the United States since September 2011. Depo-Provera is manufactured by Abbott Laboratories in Abbott-Munich, Switzerland. In July 2013, a lab test that mimics the brain that causes a brain tumor was found in the brain of women with the disorder. The Depo-Provera shot is only available in the United States.
It has been available in the U. S. since late 2019. According to the FDA, the birth control shot can be used in up to 80% of women with the disorder. However, in some women, the birth control shot may not be used due to safety concerns about side effects.
The Depo Provera shot has been available as an injection since 2017. As of December 2019, the Depo Provera shot is in the United States market. In December 2017, the company announced that the birth control shot is no longer available as a generic. In April 2018, the Depo-Provera shot was discontinued from the market due to legal concerns about the use of the birth control shot, with the Depo-Provera shot remaining in the market for about 20% of women with the disorder.
The Depo-Provera shot is only available as an injectable and may not be used in the U. for women at risk of the disorder. The Depo-Provera shot is only available to women with a uterus who are not a sexually active person and who have a history of multiple pregnancies.
Depo-Provera shot is only available for women who are not a sexually active person. According to the company, the drug is only available for women who have a history of multiple pregnancies.
A study conducted by the National Institute for Health Care Management Research has shown that Depo-Provera is the only contraceptive pill that is approved in the U. and has a potential for long-term use for women with the disorder.
The FDA approved Depo-Provera in September 2014.
According to the FDA, the birth control shot is only available in the U. and is not indicated for use by women with the disorder. In the U. S., the birth control shot is only available in the U.
The Depo-Provera shot is only available to women who are not a sexually active person. S., the birth control shot is only available to women who have a history of multiple pregnancies.
The birth control shot can only be used as part of an injection if there is no other method of contraception available or the birth control shot is considered inappropriate.
According to the FDA, the Depo-Provera shot is only available for women who are not a sexually active person. The Depo-Provera shot is only available for women who have a history of multiple pregnancies.
A study conducted by the National Institute for Health Care Management Research has shown that the birth control shot is the only contraceptive pill that is approved in the U.
The Depo-Provera shot is only available for women who are not a sexually active person. S., the birth control shot is only available for women who have a history of multiple pregnancies.
According to the FDA, the birth control shot is the only contraceptive pill that is approved in the U.
Depo-Provera is a type of hormone that is often used to prevent pregnancy. It prevents ovulation in women who have an abnormal uterine bleeding and is used to stop the ovaries from releasing an egg.
You may need a prescription from a doctor or a pharmacy to get Depo-Provera. You should only take it if your doctor has prescribed it for you.
It can take up to six months for the medicine to start to work. You will need a prescription to get Depo-Provera if you have been diagnosed with the condition.
You should not take Depo-Provera if you are not sure you should.
The dose of Depo-Provera varies based on age and other factors. It can be taken with or without food.
If you are taking Depo-Provera, you should tell your doctor if you have any of the following medical conditions:
If you are pregnant, are trying to get an abortion or think you might be pregnant, or are planning to get pregnant, talk with your doctor.
Depo-Provera can affect the way a person responds to other treatments.
Stade de France Pharmacy